Increasing drug safety by implementing Celon Pharma S.A. in its own production innovative oral forms of three medicinal products used in the pharmacotherapy of cardiovascular diseases

FGF1 analogue: a new therapeutic target for non-alcoholic fatty liver disease and related metabolic diseases

Develop clinical candidates based on mRNA technology in 3 therapeutic areas (oncological, metabolic - AATD deficiency and viral - SARS-CoV2), as well as to develop and expand the competence of Celon Pharma S.A. in the area of pharmaceutical production in the area of mRNA

  CELONKO – "Development of modern biomarkers and development of an innovative FGFR kinases inhibitor"

Preclinical and clinical development of a first-in-class, innovative, bispecific immunotherapeutic agent as a drug candidate in cancer immunotherapy 

Development of an innovative, class-leading, low-molecular, double-oriented therapeutic agent having immunomodulating and cytotoxic effects as a drug candidate for the treatment of leukaemia and solid tumours

Development of an innovative platform for the production of bispecific constructions based on Phage Display technique and the preclinical and clinical development of an innovative bispecific drug candidate for the treatment of inflammatory diseases

Preclinical and clinical development of the innovative PI3 delta kinase inhibitor as a candidate in the treatment of inflammatory diseases

UBA – Preclinical and clinical development of the ubiquitin-proteasome system inhibitor as an innovative drug used in cancer treatment.

AMDBP – Development of a production platform for biosimilars based on CHO cells and an innovative expression system and preclinical and clinical development of a biosimilar drug based on a Fab fragment.

GATE – Preclinical and clinical development of an innovative antagonist of GPR40 receptor in type 2 diabetes treatment

FAIND – A new diabetes treatment using an innovative FGF1 protein analogue.

A new form of S-ketamine in treatment of depression

JAKSON – Selective JAK/ROCK kinases inihibitor in treatment of immune-mediated diseases

“Fostering Celon Pharma S.A. research infrastructure by creating a Research&Development Centre (RDC)”

  NoteSzHD – "New therapy in psychotic disorders and Huntington's disease with special focus on cognitive deficits" .

  NATco – "New anti-amyloid therapy for cognitive disorders"

Implemented projects

TrackB - Preclinical and clinical development of innovative TrkB antagonist in treatment of nervous system disorders.

PIKCel – developing inhalation technology in asthma and COPD treatment